Nitroglycerin is 1,2,3-propanetriol, trinitrate, an organic nitrate.
Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack.
Published Studies Related to Transderm Nitro (Nitroglycerin Transdermal)
Effect of the Addition of Vasopressin or Vasopressin Plus Nitroglycerin to Epinephrine on Arterial Blood Pressure during Cardiopulmonary Resuscitation in Humans. [2011.11]
Background: Infusion of a vasopressor during cardiopulmonary resuscitation (CPR) in humans increases end decompression (diastolic) arterial blood pressure, and consequently increases vital organ perfusion pressure and survival.
Nitroglycerin Ointment for the Prevention of Postmenopausal Osteoporosis (December). [2011.10.18]
OBJECTIVE:To determine whether clinical trial data support the use of nitroglycerin for prevention of postmenopausal osteoporosis.DATA SOURCES:A literature search using MEDLINE (1966-September 2011) and EMBASE (1973-September 2011) was conducted using the search terms nitroglycerin, bone mineral density, fracture, and osteoporosis...
The effect of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in acute/subacute stroke. [2011.08]
BACKGROUND: High blood pressure is a common complication in acute stroke and is associated with a poor outcome. Aims This study assesses the effects of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in patients with recent stroke... CONCLUSIONS: Transdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke. This reduction in blood pressure is clinically relevant and is unlikely to be excessive. (c) 2011 The Authors. International Journal of Stroke (c) 2011 World Stroke Organization.
Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. [2011.07]
CONCLUSIONS: The differential modulation effects of cystatin-C and interleukin-6 but not other inflammatory markers, in response to NES compared with NTG therapy, may provide important implications for vasodilator therapy. Further studies are warranted to confirm these findings. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00842023.
Short-term aerobic exercise reduces nitroglycerin-induced orthostatic intolerance in older adults with type 2 diabetes. [2011.06]
AIMS/HYPOTHESIS: Older adults are at a high risk for syncope due to orthostatic intolerance (OI), and this risk increases with comorbid type 2 diabetes and vasoactive medications. Despite many benefits, previous investigations have shown worsening OI with aerobic training. We examined whether aerobic exercise reduced OI in older adults with type 2 diabetes who were given a short-acting vasoactive agent (nitroglycerin)... CONCLUSIONS: Our findings indicate that a relatively short aerobic exercise intervention can improve postnitroglycerin orthostatic tolerance in older adults with type 2 diabetes.
Clinical Trials Related to Transderm Nitro (Nitroglycerin Transdermal)
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Terminated]
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) [Active, not recruiting]
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in
adults with PC. Subjects may receive either placebo or treatment with at least 1 foot
receiving topical sirolimus at some time. For certain phases of the study treatment
assignment to the right and left foot will be randomized in a double blind fashion. Blood
levels will test systemic absorption of sirolimus. Other safety and efficacy measures will
be taken through the 39-week study duration. Funding Source - FDA OOPD
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita [Completed]
Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder affecting the
nails, skin, oral mucosae, larynx, hair and teeth. Pathogenic mutations in keratin K6a, K6b,
K16 or K17 act via a dominant negative mechanism, leading to manifestations of the disease.
The most disabling PC symptom is a painful plantar blistering and keratoderma that requires
use of ambulation devices in more than 50 percent of patients. Despite our understanding of
the molecular basis of PC, current treatment is limited to mechanical removal of the thick
calluses, non-specific topical keratolytics, and oral retinoids, none of which alleviates
blistering or plantar pain satisfactorily. A public charity, PC Project, has been founded to
support the development of treatments for PC (www. pachyonychia. org). In collaboration with
this charity, a small company, TransDerm, Inc., has developed a small interfering RNA
(siRNA) that specifically targets a mutation in one of the PC keratins, K6a. As this siRNA
targets a single nucleotide mutation, it will only be effective against PC subjects
harboring this specific mutation. There are currently only six known patients who carry this
mutation in the International Pachyonychia Congenita Research Registry, but three of these
patients live in Salt Lake City (a mother and two of her children). We propose to perform a
Phase Ib clinical trial to test the safety and tolerability of TD101 in PC patients carrying
an N171K mutation. We will complete treatment of the adult patient prior to recruitment of
Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) [Recruiting]
The primary objective of this study is to assess the safety of topical sirolimus (TD201) 1%
for plantar keratoderma for the treatment of pachyonychia congenita. This study would also
like to assess the potential of sirolimus (TD201) to improve the clinical severity of
plantar keratoderma, including pain.
Page last updated: 2011-12-09